共 50 条
- [21] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple MyelomaBLOOD, 2015, 126 (23)Shah, Jatin J.Feng, LeiWeber, DonnaThomas, Sheeba K.Wang, MichaelTurturro, FrancescoQazilbash, Muzaffar H.Shah, NinaBashir, QaiserPopat, Uday R.Manasanch, Elisabet E.Munoz, Silvia C.Landry, AshleyMendoza, KathleenNieto, YagoChamplin, Richard E.Orlowski, Robert Z.
- [22] Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple MyelomaBLOOD, 2017, 130Patel, Krina K.Shah, Jatin J.Feng, LeiLee, Hans C.Manasanch, Elisabet E.Thomas, Sheeba K.Weber, Donna M.Munoz, Silvia C.Morphey, AshleyBashir, QaiserQazilbash, Muzaffar H.Orlowski, Robert Z.
- [23] Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantationHAEMATOLOGICA, 2001, 86 (04) : 409 - 413Tosi, PRonconi, SZamagni, ECellini, CGrafone, TCangini, DPileri, SABaccarani, MTura, SCavo, M
- [24] Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myelomaAnnals of Hematology, 2011, 90 : 1161 - 1166Marek HusNorbert GrzaskoMarta SzostekAndrzej PlutaGrzegorz HelbigDariusz WoszczykMaria Adamczyk-CiochDariusz JawniakWojciech LegiecMarta MorawskaJustyna KozinskaPiotr WacińskiAnna Dmoszynska
- [25] Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myelomaANNALS OF HEMATOLOGY, 2011, 90 (10) : 1161 - 1166Hus, MarekGrzasko, NorbertSzostek, MartaPluta, AndrzejHelbig, GrzegorzWoszczyk, DariuszAdamczyk-Cioch, MariaJawniak, DariuszLegiec, WojciechMorawska, MartaKozinska, JustynaWacinski, PiotrDmoszynska, Anna
- [26] Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myelomaAnnals of Hematology, 2011, 90 : 1449 - 1456Massimo OffidaniLaura CorvattaClaudia PolloniSilvia GentiliAnna MeleRita RizziMassimo CatariniPatrizia CaraffaArduino SamoriNicola BlasiMario FerrantiLara MalerbaMarino BrunoriPietro Leoni
- [27] Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma PatientsBLOOD, 2021, 138Garderet, LaurentKuhnowski, FrederiqueBerge, BenoitRoussel, MurielleEscoffre-Barbe, MartineLafon, IngridFacon, ThierryLeleu, XavierKarlin, LionelPerrot, AuroreMoreau, PhilippeMarit, GeraldStoppa, Anne-MarieRoyer, BrunoChaleteix, CarineTiab, MouradAraujo, CarlaLenain, PascalMarco, MargaretVoog, Eric G.Benboubker, LotfiAllangba, Olivier ThierryJourdan, EricOrsini-Piocelle, FrederiqueBrechignac, SabineEveillard, Jean-RichardBelhadj, KarimWetterwald, MarcPegourie, BrigitteJaccard, ArnaudEisenmann, Jean ClaudeGlaisner, SylvieMohty, MohamadHulin, CyrilleLoiseau, Herve AvetMathiot, ClaireAttal, Michel
- [28] First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myelomaHAEMATOLOGICA, 2004, 89 (07) : 826 - 831Cavo, MZamagni, ETosi, PCellini, CCangini, DTacchetti, PTestoni, NTonelli, MDe Vivo, APalareti, GTura, SBaccarani, M
- [29] Initial Treatment with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)BLOOD, 2008, 112 (11) : 1273 - 1273Jakubowiak, AndrzejKendall, TaraAl-Zoubi, AmmarKhaled, YasserMineishi, ShinBrozo, ChristineCampagnaro, EricaTalpaz, MosheKaminski, Mark S.
- [30] SEQUENTIAL VAD (VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) AND VTD (BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE TREATMENT WITH BORTEZOMIB FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (A PHASE II TRIAL)HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 148 - 148Yoon, S. S.Kim, H. J.Lee, D. S.Sohn, S. K.Eom, H. S.Lee, J. L.Chung, J. S.Kim, K.Suh, C. W.Won, J. H.Kim, J. S.Park, J. S.Kang, H. J.Seong, C. M.Kim, C. S.Lee, S. J.Lee, J. H.Yoon, H. J.